Orion Oyj Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 2/17/2026)
| Balance Sheet | Total Assets | 2,009,900,000.00 | ROE | 63.91 % |
| Balance Sheet | Total Equity | 1,284,500,000.00 | ROA | 24.89 % |
| Cashflow | Capital Expenditures | -97,600,000.00 | P/FCF | 55.17 |
| Cashflow | Free Cash Flow | 219,200,000.00 | – | – |
| Cashflow | Operating Cash Flow | 316,800,000.00 | P/CF | 38.17 |
| Income | Earnings per Share (diluted) | 3.56 | Div. Yield | 2.09 % |
| Income | Net Income | 500,300,000.00 | P/E | 24.14 |
| Income | Shares Outstanding | 140,866,100.00 | P/B | 9.41 |
| Income | Total Revenue | 1,889,500,000.00 | P/S | 6.40 |
Ratios calculated on: 10/14/2026
Company Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company has a collaboration with Nanoform to apply Nanoform's CESS technology to new chemical entities. It serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) line of inhalers for asthma and COPD to Propeller's digital medicine platform; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj is headquartered in Espoo, Finland.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.orion.fi
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more